Fungal Glucosylceramide as a Vaccine for Fungal Infections


Fungal infections pose a significant threat to public health. Fungi are common in the environment, as they can thrive in soil, on plants and trees, and on animate objects, including human skin. Despite the availability of antifungal agents, morbidity and mortality from invasive fungal infections remain high, particularly in critically ill patients. Successfully eliminating fungal pathogens following prophylactic or therapeutic immunization depends largely on the ability of the host?s immune system to become appropriately activated in response to the immunization and to mount an effective response that does not significantly damage healthy tissue. A need exists for the development of, and improvement of, fungal vaccines.


Researchers in the Department of Molecular Genetics and Microbiology at Stony Brook University invented a technology that uses a purified lipid extracted from nonpathogenic fungal cells as an antigen to stimulate the host immunity so that the host becomes protected when exposed to pathogenic fungal cells.


Increased and longer protection against the infection caused by Cryptococcus neoformans.


Protection against the infection caused by pathogenic fungal cells.

Patent Status

Patent application submitted

Stage Of Development

Proof of concept data is available. US Utility application filed (#15/515,318)

Licensing Potential

Development partner - Commercial partner - Licensing

Licensing Status

Available for license. Seeking to develop and commercialize, by an exclusive or non-exclusive license agreement and/or sponsored research, with a company active in the area.

Additional Info

Additional Information: Source: CDC,, CC0.
Patent Information:
Case ID: R8480
For Information, Contact:
Sean Boykevisch
State University of New York at Stony Brook
Maurizio Del Poeta
Visesato Mor
fungal infection